Y-mAbs Therapeutics Community

NasdaqGS:YMAB Community

1 Narratives written by author
0 Comments on narratives written by author
3 Fair Values set on narratives written by author

Y-mAbs Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 10 Analysts

DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities

Key Takeaways Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units. Expanding U.S. and international sales and exploring new indications could significantly boost future revenue and pipeline growth drivers.

US$17.00

FV

72.4% undervalued

8.45%

Revenue growth p.a.

0

0

3

2 days ago